Veracyte, Inc.
NGM: VCYTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Veracyte, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VCYT Z-Score →About Veracyte, Inc.
Healthcare
Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Veracyte, Inc. demonstrates a healthy profit margin of 12.8%.
The company recently reported 18.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 5.3%, which suggests room for improvement in capital utilization.
At a current price of $31.09, VCYT currently sits at the 30th percentile of its 52-week range (Range: $22.61 - $50.71).
💰 Valuation Insight
VCYT trades at a 51.7% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.47B
Trailing P/E
37.91
Forward P/E
17.55
Beta (5Y)
1.96
52W High
$50.71
52W Low
$22.61
Avg Volume
919K
Day High
Day Low